1. |
Prondzynski M, Mearini G, Carrier L. Gene therapy strategies in the treatment of hypertrophic cardiomyopathy. Pflugers Arch, 2019, 471(5): 807-815.
|
2. |
Task Force Members, Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J, 2014, 35(39): 2733-2779.
|
3. |
Liu LW, Zuo L, Zhou MY, et al. Efficacy and safety of transthoracic echocardiography-guided percutaneous intramyocardial septal radiofrequency ablation for the treatment of patients with obstructive hypertrophic cardiomyopathy. Chin J Cardiol, 2019, 47(4): 284-290.
|
4. |
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2020, 142(25): e533-e557.
|
5. |
Liu L, Li J, Zuo L, et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol, 2018, 72(16): 1898-1909.
|
6. |
國家心血管病中心心肌病專科聯盟, 中國醫療保健國際交流促進會心血管病精準醫學分會 "中國成人肥厚型心肌病診斷與治療指南2023" 專家組. 中國成人肥厚型心肌病診斷與治療指南2023. 中國循環雜志, 2023, 38(1): 1-33.The Joint Committee of Cardiomyopathy Specialty Alliance, National Center for Cardiovascular Diseases/Cardiovascular Precision Medicine Branch of China International Exchange and Promotive Association for Medical and Health Care. 2023 guideline for diagnosis and treatment of patients with hypertrophic cardiomyopathy. Chin Circ J, 2023, 38(1): 1-33.
|
7. |
李瑩. Liwen術式治療梗阻性肥厚型心肌病對心律失常的影響及相關影響因素. 中國人民解放軍空軍軍醫大學, 2024.Li Y. Effect of Liwen procedure on arrhythmias and related influencing factors in hypertrophic obstructive cardiomyopathy. Air Force Medical University, 2024.
|
8. |
Wei X. Progress in the surgical treatment of hypertrophic obstructive cardiomyopathy. J Clin Surg, 2023, 31(9): 801-803.
|
9. |
李曉藝, 吳宏祥, 王若冰, 等. 改良Morrow術治療兒童肥厚型梗阻性心肌病遠期療效的單中心回顧性研究. 中國胸心血管外科臨床雜志, 2024, 31(7): 985-990.Li XY, Wu HX, Wang RB, et al. Long-term effect of modified Morrow surgery on hypertrophic obstructive cardiomyopathy in children: A retrospective study in a single center. Chin J Clin Thorac Cardiovasc Surg, 2024, 31(7): 985-990.
|
10. |
李丹, 郗昆, 孟繁宇, 等. 老年肥厚型梗阻性心肌病患者血清肌鈣蛋白Ⅰ和N末端B型利鈉肽原水平及其與心臟重構的關系. 中國老年學雜志, 2020, 40(22): 4718-4720.Li D, Xi K, Meng FY, et al. Serum troponin I and N-terminal B-type natriuretic peptide levels and their relationship with cardiac remodeling in elderly patients with hypertrophic obstructive cardiomyopathy. Chin J Gerontol, 2020, 40(22): 4718-4720.
|
11. |
Falasconi G, Pannone L, Slavich M, et al. Atrial fibrillation in hypertrophic cardiomyopathy: Pathophysiology, diagnosis and management. Am J Cardiovasc Dis, 2020, 10(4): 409-418.
|
12. |
穆玉明, 南晶. 肥厚型心肌病心肌灌注與心肌力學的研究現狀與進展. 中華醫學超聲雜志(電子版), 2020, 17(5): 391-393.Mu YM, Nan J. Research status and progress of myocardial perfusion and myocardial mechanics in hypertrophic cardiomyopathy. Chin J Med Ultrasound (Electron Ed), 2020, 17(5): 391-393.
|
13. |
Vainrib A, Massera D, Sherrid MV, et al. Three-dimensional imaging and dynamic modeling of systolic anterior motion of the mitral valve. J Am Soc Echocardiogr, 2021, 34(1): 89-96.
|